APLM Apollomics, Inc. Gross Profitability

Official company branding of Apollomics, Inc. (APLM)

Apollomics, Inc. (APLM) maintains stable management that is successfully advancing oncology programs by leveraging obtained orphan statuses. The company is developing a personalized treatment system for lung and liver tumors. The gross margin share of revenue illustrates cost efficiency, with the latest figure standing at 0.00. This confirms the strategy for the global expansion of webreltinib's presence in the Chinese and US markets to capture new segments.

Gross Profitability: Apollomics Corp (APLM) for 02/21/2024 - 11/19/2026

Financial and market metric breakdowns for Apollomics Corp (APLM)

- share price and consensus valuation forecast:
Basic company analysis:APLM - Apollomics
Mass-produced product of Apollomics Inc.

Apollomics, Inc. generates current cash flow through partnerships as it prepares to bring its own oncology drugs to market. The gross margin quantifies the efficiency of this model by measuring the portion of revenue remaining after direct production costs, allowing investors to assess the fundamental profitability of each product unit through gross profit margin dynamics.

Key competitors

Gross Profit Margin BeiGene Ltd. (ONC)|Return on Gross Profit HALO|Gross Profitability RVMD|Return on Gross Profit AAPG (Ascentage)|Return on Gross Profit cgoncology.com CGON|UroGen Pharma - Return on Gross Profit|Gross Profit Rate BCAX|PSNL - Gross Profitability|Return on Sales by Gross Profit Erasca Oncology ERAS|delcath.com (DCTH) - Gross Profitability|Y-mAbs Therapeutics - Gross Profit Rate|AURA (Aura Biosciences Inc) - Gross Margin|Gross Profit Margin candeltx.com CADL|Gross Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Gross Profit Rate|Gross Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Gross Profitability|TuHURA Biosciences Inc. - Gross Margin|TARA - Gross Margin|FATE (Fate Therapeutics) - Return on Gross Profit|Return on Gross Profit Aadi Bioscience, Inc.|Return on Gross Profit TCRX|Gross Profitability CSBR|Gross Margin XBIT|Return on Sales by Gross Profit CEL-SCI Corp.|Gross Profitability ostherapies.com OSTX|RADX: Gross Return on Sales|ARTV: Return on Gross Profit|ANL (Adlai Nortye) - Gross Return on Sales|Veru (VERU) - Gross Profitability|Return on Gross Profit Tempest Therapeutics Inc|Gross Profitability Xilio Therapeutics|Gross Return on Sales RENB (Renovaro Inc.)|Gross Profitability Mural Oncology PLC (MURA)|Gross Margin Kairos Pharma (KAPA)|Gross Profitability onkuretherapeutics.com OKUR|GDTC: Gross Return on Sales|CRIS: Return on Gross Profit|Tharimmune Corp (THAR) - Return on Gross Profit|ADVB: Gross Margin|Return on Gross Profit Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Gross Margin|Gross Return on Sales SBFM (Sunshine Biopharma)|Gross Profitability Xenetic Bio (XBIO)|Gross Profitability SLRX (Salarius Pharma)|Kitov Pharma - Return on Gross Profit|American Oncology Network (AONC) - Gross Profit Margin|BeiGene - Gross Margin|Checkpoint Therapeutics, Inc. (CKPT) - Return on Gross Profit|ELEV (Elevation Oncology, Inc.) - Return on Gross Profit|iCAD Inc. - Gross Profit Rate|Return on Gross Profit IKNA|Gross Margin notablelabs.com|Return on Gross Profit VIRX (Viracta Therapeutics Inc.)|MOR - Gross Profit Margin|Gross Profitability NAYA Biosciences NAYA|AAPGV - Return on Gross Profit